Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
NCT06855095

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

Led by The Netherlands Cancer Institute · Updated on 2025-03-03

39

Participants Needed

1

Research Sites

139 weeks

Total Duration

On this page

Sponsors

T

The Netherlands Cancer Institute

Lead Sponsor

N

Neuroendocrine Tumor Research Foundation

Collaborating Sponsor

AI-Summary

What this Trial Is About

According to current guidelines, patients have to withhalt long-acting somatostatin analogues (LA-SSA) for 4-6 weeks prior to every 177Lutetium-DOTATATE administration. The primary objective of the study is to investigate the effect of LA-SSA on the absorbed dose in tumor lesions during PRRT.

CONDITIONS

Official Title

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 218 years or older
  • Able to provide spoken and written informed consent for the trial
  • Histopathological confirmed neuroendocrine tumor
  • Meet clinical criteria for PRRT
  • At least one soft tissue lesion larger than 2 cm
  • Planned administered activity of 7400 MBq
  • ECOG performance status score between 0 and 2
Not Eligible

You will not qualify if you...

  • Unable to stop long-acting somatostatin analogue treatment for 4-6 weeks
  • Use of short-acting somatostatin analogues
  • Pregnancy or currently breastfeeding
  • Unable to follow study procedures
  • Conditions that could affect drug biodistribution, such as need for furosemide right after PRRT, limited fluid intake, or presence of renal catheters

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Antoni van Leeuwenhoek

Amsterdam, Netherlands

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here